34 results about "Inflammatory lung disease" patented technology

The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds of Formula II in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.whereinX is S, N, O or CR;Y is CRR′, O, NR6, CRR′—CRR′ or CR═CR;Z is NR6, O, S, CRR′ or CRR′—CRR′;R1-R3 are independently selected from the group consisting of H, C1-C8 alkyl, C1-C8 alkoxy, amino, hydroxy, halosubstituted alky and halo;R4 isQ is CR, NR6 orR5 is H or benzyl;R6 is H, C1-C8 alkyl, C1-C8 alkoxy, OH or halo; andR and R′ are independently H, C1-C8 alkyl, C1-C8 alkoxy, OH or halo,or a pharmaceutically acceptable salt thereof.

The invention provides compositions comprising mesenchymal stem cell (MSC) derived exosomes, and methods of their use in subjects having certain lung diseases including inflammatory lung disease.

The present invention relates to N-acetylcysteine compositions and methods for treating inflammation and redox imbalance in acute exacerbations of inflammatory lung disease.

The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided.

The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.

Disclosed herein are compositions containing hydroxylstilbenes or their derivatives or analogues. The compositions are useful to inhibit protein kinease, and for the treatment of inflammatory diseases, including psoriasis, multiple sclerosis, rhumatoid arthritis, restinosis, inflammatory bowel disease, and inflammatory lung disease. They are also useful to treat surgical adhesions and graft rejection. Novel derivatives and analogues are also disclosed.

The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.

The invention discloses a cycloalkane thiophthene derivative and pharmaceutically acceptable salts, metabolic products or prodrugs thereof. A compound can be used for treating diseases related with STAT3 (Signal Transducer and Activator of Transcription 3) activation, such as ovarian cancer, endometrial cancer, cervical cancer, breast cancer, colon cancer, pancreatic cancer, lung cancer, brain cancer, prostate cancer, kidney cancer, liver cancer, bladder cancer, oral cancer, sarcoma, prostate cancer, head and neck squamous cell carcinoma, neuroglioma, melanoma, lymphoma, leukemia, and renal fibrosis, pulmonary fibrosis, rheumatoid arthritis, hair growth, arthritis, psoriasis, lupus erythematosus, inflammatory lung diseases and inflammatory bowel diseases. (The formula is shown in the description.).

The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided.

A screening method for identifying a target nerve to ablate in the treatment of inflammatory lung disease including chronic obstructive pulmonary disease and asthma. The method includes advancing a tool along the airway and into the vicinity of the candidate nerve. The candidate nerve is temporarily blocked or paralyzed. The patient is monitored for an adverse reaction during the step of temporarily blocking. If an adverse reaction is not observed, the candidate nerve is identified as the target nerve. In embodiments, the method further includes the step of ablating the target nerve.

The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the prevention and curative treatment of an inflammatory pulmonary disease.

Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and / or the genetic analysis of the INPP4A gene in a population. The invention also provides an association with the expression profile of INPP4A protein in the mouse model of asthma. Specifically, the invention provides a method for detection of predisposition to atopic disorders / other immunological disorders such as, autoimmune disorders, inflammatory disorders, cancer, multiple sclerosis, fibrosis, tuberculosis, sarcoidosis, hypertension and disorders developing due to hypertension, diabetes and disorders developing due to diabetes, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease (COPD), cholecystectomy, degenerative joint disease (DJD), seizure disorder, arthritis, etc. where human Inositol polyphosphate 4-phosphatase (INPP4A) might play an important role due to its involvement in platelet action.

The invention discloses application of a calpain inhibitor to preparation of medicine for relieving lung inflammation caused by cigarette smoke. After the calpain inhibitor calpeptin is used for performing intraperitoneal injection on a passive smoking mouse and treating BEAS-2B cells treated by cigarette smoke extracts, the increase of lung and in vitro bronchus epithelial cell inflammation caused by cigarette smoke can be obviously relieved. Therefore the calpain inhibitor can be used for preparing medicine for relieving lung inflammation increase caused by cigarette smoke; potential and good application prospects are realized in the field of inflammatory lung disease treatment.

The invention provides a synthesized recombinant human CC16 gene shown as SEQ ID NO.1, construction of a eukaryotic expression recombinant plasmid containing the CC16 gene, and production of purified recombinant human CC16 protein after cell transfection. The obtained recombinant human CC16 protein can inhibit PLA2 activity, so that a condition is created by using the recombinant protein to realize intervention therapy on inflammatory lung diseases.

Not only acute or chronic interstitial pneumonia and plumonary fibrosis but also chronic obstructive plumonary diseases, such as plumonary emphysema and chronic bronchitis, can be effectively prevented or treated by inhalation administration to the lung tissue of 2-{N-[4-(4-chlorobenzenesulfonylamino)butyl]-N-{3-[(4-isopropyl 2-thiazolyl)methoxy]benzyl}}-sulfamoylbenzoic acid or a pharmacologically acceptable salt thereof.

The invention described herein relates to methods of screening for pro-inflammatory genes and anti-inflammatory genes which may be useful for treating an inflammatory disease, disorder, or otherwise abnormal condition, such as an inflammatory lung disease. The identified pro-inflammatory genes and anti-inflammatory genes may be used to produce pharmaceutical compositions for use in treating the inflammatory disease, disorder, or otherwise abnormal condition.

The present invention relates to preventing, or treating and / or reducing the severity or progression of Type 1 immune response-mediated inflammatory lung disease. More particularly, the present invention provides a method for preventing or treating chronic obstructive pulmonary disease (COPD), severe asthma, sarcoidosis, berylliosis or cystic fibrosis by neutralizing or reducing IFNγ bioactivity which can be achieved either by in vivo administration of IFNγ neutralizing molecules or by in vivo immunization with pharmaceutical compositions comprising immunogenic IFNγ proteins or IFNγ-derived (poly)peptides or their corresponding nucleic acid sequences.

The present invention relates to the application of nicotinic receptor agonist or its analog or derivative in the treatment of inflammatory lung diseases. The invention further relates to pharmaceutical compositions comprising a nicotinic receptor agonist or an analogue or derivative thereof. Also provided are novel compounds of the general formula wherein R1, R2, Xa and Ya are as defined herein.

The invention discloses compositions and methods for treating COPD and other inflammatory conditions. The present invention features, inter alia, pharmaceutical compositions and their use in the preparation of a medicament (e.g., a medicament for inflammation, such as an inflammatory lung disease) or in a therapeutic regimen. The compositions can include at least two active agents: a first agent that inhibits PDE4 (e.g., roflumilast) and a second active agent that inhibits the expression or activity of one or more PDE4B variants (e.g., PDE4B2). The compositions and methods will attenuate an unwanted up-regulation of a PDE4B (e.g., PDE4B2) and may thereby improve treatment with the first agent (e.g., roflumilast). For example, the second agent may improve the efficacy of the first agent, decrease the effective dose of the first agent, ameliorate the tolerance to the first agent that would otherwise develop (e.g., in patients with COPD exacerbation), reduce unwanted side effects caused by the first agent, or otherwise improve treatment regimes including a PDE4 inhibitor.

The present invention provides an inflammatory lung disease agent capable of effectively preventing and / or treating inflammatory lung diseases, and more specifically, to a prophylactic and / or therapeutic agent for inflammatory lung diseases, comprising, as an active ingredient, an antibody or an antibody fragment having antigen-binding activity with respect to S100A8 / A9 heterodimers. By blocking the interaction between S100A8 / A9 and its receptor group, inflammatory lung diseases can be effectively prevented and / or treated. Specifically, by blocking the interaction between S100A8 / A9 and RAGE, which is a receptor thereof, the expression of NF-[kappa] B, which induces the expression of various inflammatory cytokines as a transcription factor downstream of RAGE, is inhibited, and the proliferation of activated fibroblasts is inhibited, and further, by inhibiting the differentiation of activated fibroblasts into myofibroblasts, the proliferation of myofibroblasts is inhibited. The inflammatory lung diseases can be effectively prevented and / or treated. In addition, the prophylactic and / or therapeutic agent for inflammatory lung disease according to the present invention can be suitably used as a prophylactic and / or therapeutic agent for COVID-19.

TCDO can be composed of stabilized chlorite ions that target white blood cells to balance the immune system. TCDO may be applied nasally or via inhaler directly to the nasal passages or the lungs to treat lung diseases. TCDO can be provided in 20-mL vials as a sterile, clear, colorless, odorless, isotonic aqueous solution for intravenous, nasal, or lung administration.

The resent invention relates to nanovesicles derived from bacteria of genus Rhodococcus, and a use thereof. The present inventors experimentally ascertained that vesicles in clinical samples of patients with lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD and dementia are significantly reduced compared to those of normal people, the secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles is significantly inhibited when the vesicles separated from the strain are administered, and vesicles derived from bacteria of the genus Rhodococcus significantly inhibit cranial nerve cell damage caused by stress hormones, and thus vesicles derived from bacteria of the genus Rhodococcus, according to the present invention, are expected to be effectively usable for the purpose of developing a method for diagnosing lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD and / or dementia, and a composition for preventing or treating malignant disease, diabetes, stroke, cardiovascular disease, inflammatory lung disease, and / or cranial nerve diseases.

The present invention provides plant-made elafin-Fc fusion proteins for treating inflammatory diseases, e.g., inflammatory lung diseases. In certain embodiments, the fusion proteins comprise one or more point mutations, which confer improved properties, such as increased resistance to oxidation, cleavage, and increased half-life. The present invention additionally provides polynucleotides encoding the fusion proteins, recombinant cells and expression vectors, and transgenic plants comprising the fusion protein coding sequences. The present invention further provides methods for the production of the fusion proteins.

The present invention relates to compositions comprising cationic polymers and their use in treating inflammatory lung diseases characterized by the recruitment of blood neutrophils in the airways favoring the formation of a thick, mucoid or mucopurulent sputum as found in cystic fibrosis.

The invention relates to prolyl endopeptidase (PREP) inhibitors of formula (I) which contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system, methods for producing same, the use thereof alone or in combinations for treating and / or preventing diseases, and the use thereof for producing drugs for treating and / or preventing diseases, in particular for treating and / or preventing inflammatory lung diseases (COPD).